E2F3 transcription factor: A promising biomarker in lung cancer

Ahmed, Hatem Abdel Moniem; Nada, Ola

doi:10.3233/cbm-160196

Cited by 36 publications

(35 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…E2F3 (Fig. 3A) was predicted as a primary target of miR-433 and selected for investigation, to further verify its previously reported contribution to NSCLC formation and progression (26)(27)(28)(29)(30). To confirm this hypothesis, luciferase reporter assays were performed using A549 and H460 cells cotransfected with miR-433 mimics or miR-NC and pMIR-Wt-E2F3-3'-UTR or pMIR-Mut-E2F3-3'-UTR.…”

Section: E2f3 Is a Direct Target Of Mir-433 In Nsclcmentioning

confidence: 78%

“…E2F3 activation serves important roles in carcinogenesis and progression via the regulation of cell cycle, apoptosis, differentiation, migration and invasion (44)(45)(46). E2F3 is upregulated in NSCLC tissues, cell lines and serum (26,27) and contributes to the regulation of NSCLC initiation and progression (28)(29)(30). Hence, targeting E2F3 may provide novel and promising therapies for this aggressive cancer in particular.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

MicroRNA‑433 reduces cell proliferation and invasion in non‑small cell lung cancer via directly targeting E2F transcription factor 3

Liu

Zhang

et al. 2018

Mol Med Report

View full text Add to dashboard Cite

MicroRNAs (miRNA/miRs) have been associated with the initiation and progression of non‑small‑cell lung cancer (NSCLC). Hence, a comprehensive understanding of the association between dysregulated miRNAs and NSCLC may contribute to the identification of novel therapeutic methods for patients with NSCLC. MiRNA‑433 (miR‑433) has been reported to be dysregulated in numerous types of human cancers; however, its expression pattern, biological roles and associated mechanisms in NSCLC require further investigation. The present study aimed to detect miR‑433 expression and determine its roles and underlying molecular mechanisms in NSCLC. In the present study, reverse transcription‑quantitative polymerase chain reaction revealed that miR‑433 was significantly downregulated in NSCLC tissues and cell lines. This decreased miR‑433 expression was strongly associated with the tumor node metastasis stage and lymph node metastasis of patients with NSCLC. Cell Counting kit‑8 and cell invasion assays revealed that the resumption of miR‑433 expression decreased the proliferation and invasion of NSCLC cells. Bioinformatics analysis predicted E2F transcription factor 3 (E2F3) as a potential target of miR‑433. Luciferase reporter assay, RT‑qPCR and western blot analysis further demonstrated that E2F3 was a direct target of miR‑433 in NSCLC. E2F3 downregulation induced by small interfering RNA exhibited inhibitory effects similar to those of miR‑433 overexpression in NSCLC cells, and the restored E2F3 expression counteracted the suppressive effects on NSCLC cells induced by miR‑433 overexpression. Therefore, miR‑433 may inhibit the progression of NSCLC, at least in part, by targeting E2F3. The present study indicated that miR‑433 may be investigated as an innovative candidate target for the therapy of patients with this fatal disease.

show abstract

Section: E2f3 Is a Direct Target Of Mir-433 In Nsclcmentioning

confidence: 78%

Section: Discussionmentioning

confidence: 99%

MicroRNA‑433 reduces cell proliferation and invasion in non‑small cell lung cancer via directly targeting E2F transcription factor 3

Liu

Zhang

et al. 2018

Mol Med Report

View full text Add to dashboard Cite

show abstract

“…In view of the results we had achieved, we consulted literature to verify our findings. E2F3 mRNA levels were significantly higher in lung cancer patients in comparison with non‐cancerous lung tissues and its overexpression was related to poor prognosis . Also, CDC6 has been confirmed to be linked to DNA replication to regulate the occurrence and development of lung tumor .…”

Section: Discussionmentioning

confidence: 95%

The clinical value of miR‐193a‐3p in non‐small cell lung cancer and its potential molecular mechanism explored in silico using RNA‐sequencing and microarray data

et al. 2018

View full text Add to dashboard Cite

miR‐193a‐3p is a tumor‐related miRNA playing an essential role in tumorigenesis and progression of non‐small cell lung cancer (NSCLC). The objective of the present study was to investigate the relationship between miR‐193a‐3p expression and clinical value and to further explore the potential signaling of miR‐193a‐3p in the carcinogenesis of NSCLC. RNA‐sequencing and microarray data were collected from the databases GEO, ArrayExpress and The Cancer Genome Atlas (TCGA). Furthermore, in silico assessments were performed to analyze the prospective pathways and networks of the target genes of miR‐193a‐3p. In total, 453 cases of NSCLC patients and 476 normal controls were included in blood samples, while 920 cases of NSCLC patients and 406 normal controls were included in tissue samples. The pooled positive likelihood ratio, the pooled negative likelihood ratio and the pooled diagnostic odds ratio were calculated to reflect the diagnostic value of miR‐193a‐3p in blood and tissue samples. Moreover, the areas under the curve of the summary receiver operating characteristic curve of blood and tissue were 0.64 and 0.79, respectively. In addition, we found a lower level of miR‐193a in NSCLC tissues than in non‐cancerous controls based on TCGA. A gene ontology (GO) enrichment analysis demonstrated that miR‐193a‐3p could be related to key signaling pathways in NSCLC. Also, several vital pathways were illustrated by KEGG. Lower expression of miR‐193a‐3p in tissue samples of NSCLC may be associated with tumorigenesis and be a predictor of deterioration of NSCLC patients, and pathway analysis revealed crucial signaling pathways correlated with the incidence and progress of NSCLC.

show abstract

“…Moreover, E2F3 plays an important role in determining the time of the G1/S transition and the rate of DNA synthesis [24,25]. Early studies demonstrated that E2F3 is oncogenic in various human cancers, including breast, bladder, lung and prostate cancer [18,19,26]. E2F3 is essential in promoting the proliferation of ovarian cancer cells by initiating integral signaling of the EGFR-driven cell response [27].…”

Section: Discussionmentioning

confidence: 99%

Evaluation of peripheral blood E2F3 mRNA as a potential diagnostic biomarker in human papillary thyroid cancer

Zhao¹,

Zhao²,

Wu³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The transcription factor E2F3 plays a vital role in regulating cell cycle progression and proliferation. In addition, many reports have shown that E2F3 exerts an oncogenic role in various cancers and is a promising therapeutic target for the treatment of some human cancers. However, the value of E2F3 in the molecular diagnosis and prognosis evaluation of papillary thyroid cancer (PTC) has rarely been reported. The aim of this study was to evaluate the clinical signiﬁcance of E2F3 in the early diagnosis and monitoring of PTC.Materials and methods: Peripheral blood samples from 20 patients with PTC, 20 patients with benign thyroid lesions and 20 normal controls were collected. Peripheral blood E2F3 mRNA and thyroid sample E2F3 mRNA expression were detected by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR). The expression of E2F3 protein in normal thyroid tissue and thyroid tissue from benign thyroid lesions and PTC were detected by immunohistochemistry. The optimal cut-off value for differentiating PTC was obtained by using receiver operating characteristic (ROC) curve analysis.Results: E2F3 mRNA expression levels in peripheral blood and thyroid samples were significantly higher in PTC patients than in patients with benign thyroid lesions and normal subjects (P<0.05). Moreover, benign hyperplasia had higher E2F3 expression than normal tissue (P<0.01).There was no significant association between the level of E2F3 mRNA and aggressive clinicopathologic features of PTC, including TNM staging, extrathyroidal invasion, multifocality, and lymph node metastasis (P>0.05).With a cut-off value of 2.3, blood E2F3 mRNA showed 90% sensitivity, 60.9% specificity, a 70.5% positive predictive value, an 85.47% negative predictive value and 74.4% accuracy for discriminating PTC from benign hyperplasia disease of the thyroid and normal tissue. In addition, immunohistochemical results showed that E2F3 protein expression was also higher in the PTC group than in the other groups.Conclusions: The highest expression of E2F3 was found in peripheral blood and thyroid tissue of PTC patients. Moreover, blood E2F3 mRNA can be considered a promising diagnostic marker for discriminating PTC from benign thyroid diseases.

show abstract

E2F3 transcription factor: A promising biomarker in lung cancer

Abstract: Blood E2F3 mRNA is a sensitive diagnostic marker in lung cancer; moreover, it is a promising prognostic marker capable of efficiently discriminating early from late stages of the disease.

Cited by 36 publications

References 24 publications

MicroRNA‑433 reduces cell proliferation and invasion in non‑small cell lung cancer via directly targeting E2F transcription factor 3

MicroRNA‑433 reduces cell proliferation and invasion in non‑small cell lung cancer via directly targeting E2F transcription factor 3

The clinical value of miR‐193a‐3p in non‐small cell lung cancer and its potential molecular mechanism explored in silico using RNA‐sequencing and microarray data

Evaluation of peripheral blood E2F3 mRNA as a potential diagnostic biomarker in human papillary thyroid cancer

Contact Info

Product

Resources

About